International Myeloma Foundation Celebrates ODAC Meeting Outcome on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval of Myeloma Drugs in Clinical Trials: A Huge Win for the Global Myeloma Community.  (https://www.myeloma.org/news-events/multiple-myeloma-news/international-myeloma-foundation-celebrates-odac-meeting-outcome-minimal-residual-disease-mrd)